Bridger Management buys $60,351,909 stake in Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR) : Bridger Management scooped up 1,953,149 additional shares in Nektar Therapeutics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,517,011 shares of Nektar Therapeutics which is valued at $60,351,909.Nektar Therapeutics makes up approximately 3.64% of Bridger Management’s portfolio.

Other Hedge Funds, Including , Jacobs Levy Equity Management Inc sold out all of its stake in NKTR during the most recent quarter. The investment firm sold 11,880 shares of NKTR which is valued $203,861. Group One Trading added NKTR to its portfolio by purchasing 3,692 company shares during the most recent quarter which is valued at $63,355. Nektar Therapeutics makes up approx 0.01% of Group One Trading’s portfolio.California Public Employees Retirement System reduced its stake in NKTR by selling 6,500 shares or 3.03% in the most recent quarter. The Hedge Fund company now holds 208,300 shares of NKTR which is valued at $3,651,499. Nektar Therapeutics makes up approx 0.01% of California Public Employees Retirement System’s portfolio.Rice Hall James Associates boosted its stake in NKTR in the latest quarter, The investment management firm added 12,812 additional shares and now holds a total of 932,933 shares of Nektar Therapeutics which is valued at $14,152,594. Nektar Therapeutics makes up approx 0.78% of Rice Hall James Associates’s portfolio.

Nektar Therapeutics opened for trading at $17.85 and hit $18.12 on the upside on Thursday, eventually ending the session at $18.11, with a gain of 1.46% or 0.26 points. The heightened volatility saw the trading volume jump to 11,64,150 shares. Company has a market cap of $2,476 M.

On the company’s financial health, Nektar Therapeutics reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-0.33. The company had revenue of $32.77 million for the quarter, compared to analysts expectations of $29.36 million. The company’s revenue was up 44.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.